

LIMITED WARRANTY PROGRAM



➤ Innoviva Specialty Therapeutics, Inc.™ will replace eligible vials of GIAPREZA® (angiotensin II) free of charge in the event that a patient receiving GIAPREZA does not reach:

- An increase in mean arterial pressure (MAP) of **10 mmHg within the first 3 hours of initiation**¹
or
- A MAP of **65 mmHg within the first 3 hours of initiation**¹

**Available in 0.5 mg/mL and
2.5 mg/mL vial options**



[Click here to view the Limited Warranty Return Form](#)

SELECTED IMPORTANT SAFETY INFORMATION

Indication

GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.

Contraindications

None.

Warnings and Precautions

The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.

Please see additional Important Safety Information on the next page. Before administering, please see the accompanying Full Prescribing Information for GIAPREZA.

GIAPREZA®
(angiotensin II)
injection for intravenous infusion

LIMITED WASTAGE PRODUCT REPLACEMENT PROGRAM



Innoviva Specialty Therapeutics, Inc.™ will replace eligible vials of GIAPREZA® (angiotensin II) free of charge in the event that GIAPREZA vials are spoiled or unable to be administered due to 1 of the following events*:

- GIAPREZA was mishandled, dropped, or broken;
- GIAPREZA was inappropriately stored or frozen;
- GIAPREZA was reconstituted but not administered due to unforeseen patient condition; or
- A dosage preparation error occurred

Click here to access the Wastage Product Replacement Program Return Form†

*Limit of 7 replacement vials during a 12-month period.

†This form must be submitted within 30 days of the date on which the wastage occurred.

Additional criteria may apply. Click here for the terms and conditions of the GIAPREZA Limited Warranty Program or email warranty@istx.com. For the terms and conditions of the GIAPREZA Wastage Program, click here or email fieldops@istx.com.

SELECTED IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in $\geq 4\%$ of patients treated with GIAPREZA and $\geq 1.5\%$ more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA.

To report SUSPECTED ADVERSE REACTIONS, please contact:

La Jolla Pharmaceutical Company

1-800-651-3861 | medicalinformation@ljpc.com

U.S. Food and Drug Administration

1-800-FDA-1088 | www.fda.gov/medwatch

Please see additional Important Safety Information on the previous page. Before administering, please see the accompanying Full Prescribing Information for GIAPREZA.

Reference: 1. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med*. 2017;377(5):419-430. doi:10.1056/NEJMoa1704154



GIAPREZA® is marketed by Innoviva Specialty Therapeutics, Inc. in partnership with La Jolla Pharmaceutical Company.
©2026 Innoviva Specialty Therapeutics™. All rights reserved.
Printed in USA | PR-GIA-US-0090 | 02/26

GIAPREZA®
(angiotensin II)
injection for intravenous infusion